- Home
- PASG vs LTRN Comparison
PASG vs LTRN Comparison
Compare PASG & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PASG | LTRN |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | 27 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.0M | 22.2M |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PASG | LTRN |
|---|---|---|
| Price | $10.51 | $2.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $24.80 | N/A |
| AVG Volume (30 Days) | 30.3K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.28 | $1.11 |
| 52 Week High | $20.00 | $5.74 |
Technical Indicators
Market Signals| Indicator | PASG | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 66.48 | 56.09 |
| Support Level | $6.26 | $1.11 |
| Resistance Level | $20.00 | $2.41 |
| Average True Range (ATR) | 1.20 | 0.34 |
| MACD | 0.50 | 0.11 |
| Stochastic Oscillator | 100.00 | 92.25 |
Price Performance
Historical ComparisonAbout PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.